Cancer Research Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 3226-3230, July 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Longnecker, D. S.
Right arrow Articles by Curphey, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Longnecker, D. S.
Right arrow Articles by Curphey, T. J.

Effects of Four Retinoids in N-Nitrosobis(2-oxopropyl)amine-treated Hamsters1

Daniel S. Longnecker2, Elna T. Kuhlmann and Thomas J. Curphey

Department of Pathology, Dartmouth Medical School, Hanover, New Hampshire 03756

Four synthetic retinoids were evaluated with regard to chemoprevention of pancreatic carcinomas in carcinogen-treated hamsters. Syrian golden hamsters were given two injections of N-nitrosobis(2-oxopropyl)amine (20 mg/kg) and then were fed retinoid-supplemented diets for 1 year. The incidence of pancreatic carcinomas was lower in six of eight retinoid-fed groups than in the control group, although the differences were not statistically significant. The lowest incidence was observed in groups fed N-(4-pivaloyloxyphenyl)retinamide and N-(2-hydroxypropyl)retinamide. Testicular atrophy with decreased spermatogenesis was noted in males fed N-(2-hydroxypropyl)retinamide, N-(3-hydroxypropyl)retinamide, and N-(2,3-dihydroxypropyl)retinamide.

1 This work was supported by Contract NO1 CP 85675 from the National Cancer Institute.

2 To whom requests for reprints should be addressed.

Received 8/ 9/82. Accepted 4/11/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.